18-(4-chlorophenyl)-17-cyclohexyl-4,9-dimethyl-10,10-dioxo-10λ6-thia-1,4,9,11-tetraaza-tricyclo[11.5.2.0(16,19)]icosa-13(20),14,16(19),17-tetraene-3,12-dione | 1165793-63-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 18-(4-chlorophenyl)-17-cyclohexyl-4,9-dimethyl-10,10-dioxo-10λ6-thia-1,4,9,11-tetraaza-tricyclo[11.5.2.0(16,19)]icosa-13(20),14,16(19),17-tetraene-3,12-dione
• 英文别名: 18-(4-Chlorophenyl)-17-cyclohexyl-4,9-dimethyl-10,10-dioxo-10lambda6-thia-1,4,9,11-tetrazatricyclo[11.5.2.016,19]icosa-13(20),14,16(19),17-tetraene-3,12-dione；18-(4-chlorophenyl)-17-cyclohexyl-4,9-dimethyl-10,10-dioxo-10λ6-thia-1,4,9,11-tetrazatricyclo[11.5.2.016,19]icosa-13(20),14,16(19),17-tetraene-3,12-dione
• CAS: 1165793-63-4
• 化学式: C₂₉H₃₅ClN₄O₄S
• 分子量: 571.14
• InChiKey: KSEAGAJKXMTIIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  39
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  [2-(4-chlorophenyl)-3-cyclohexyl-6-(methoxycarbonyl)-1H-indol-1-yl]acetic acid 在 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 、 palladium 10% on activated carbon 、 水 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 20.0~80.0 ℃ 、101.33 kPa 条件下， 反应 51.0h， 生成 18-(4-chlorophenyl)-17-cyclohexyl-4,9-dimethyl-10,10-dioxo-10λ6-thia-1,4,9,11-tetraaza-tricyclo[11.5.2.0(16,19)]icosa-13(20),14,16(19),17-tetraene-3,12-dione
  参考文献：
  名称：

  Finger-loop inhibitors of the HCV NS5b polymerase. Part 1: Discovery and optimization of novel 1,6- and 2,6-macrocyclic indole series

  摘要：

  Novel conformationaly constrained 1,6- and 2,6-macrocyclic HCV NS5b polymerase inhibitors, in which either the nitrogen or the phenyl ring in the C2 position of the central indole core is tethered to an acylsulfamide acid bioisostere, have been designed and tested for their anti-HCV potency. This transformational route toward non-zwitterionic finger loop-directed inhibitors led to the discovery of derivatives with improved cell potency and pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.097

文献信息

• MACROCYCLIC INDOLES AS HEPATITIS C VIRUS INHIBITORS
  申请人：RABOISSON Pierre Jean-Marie Bernard

  公开号：US20100273792A1

  公开（公告）日：2010-10-28

  The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R 1 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  本发明涉及公式（I）的HCV复制抑制剂，N-氧化物形式，药学上可接受的加盐物，季铵盐和其立体化学异构体形式，其中R1;R3;和R4具有在权利要求中定义的含义。本发明还涉及制备所述化合物的过程，包含它们的制药组合物以及它们在HCV治疗中的使用。
• Macrocyclic Indoles as Hepatitis C Virus Inhibitors
  申请人：Janssen R&D Ireland

  公开号：US20130267511A1

  公开（公告）日：2013-10-10

  The present invention relates to inhibitors of HCV replication of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein R 1 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

  本发明涉及公式（I）的HCV复制抑制剂，N-氧化物形式，药学上可接受的加盐物，季铵盐和其立体化学异构体形式，其中R1；R3；和R4具有权利要求中所定义的含义。本发明还涉及制备所述化合物的过程，含有它们的制药组合物以及它们在HCV治疗中的使用。
• Macrocyclic indoles as hepatitis c virus inhibitors
  申请人：Janssen R&D Ireland

  公开号：EP2238142B1

  公开（公告）日：2012-07-04
• US8524716B2
  申请人：——

  公开号：US8524716B2

  公开（公告）日：2013-09-03
• US9334282B2
  申请人：——

  公开号：US9334282B2

  公开（公告）日：2016-05-10